Myocardial Injury Clinical Trial
Official title:
Evaluation for Acute and Chronic Features of Cardiac Injury by CMR in Acute CO Poisoned Patients With Elevated Troponin I (TnI)
Previous report showed that 37% of patients with moderate to severe carbon monoxide (CO)
poisoning experienced a myocardial injury, defined as elevated cardiac enzyme [creatine
kinase, CK-MB, and cardiac troponin I (TnI)] or ischemic electrocardiogram (ECG) change. In
other study, 24% of the patients with the myocardial injury after CO poisoning died during a
median follow-up of 7.6 years. The myocardial injury was the major predictor of mortality. In
addition, in the Taiwanese nationwide population-based cohort study, CO poisoning itself
reported as a higher risk of a major adverse cardiovascular event.
According to the previous study of investigators, among CO poisoned patients with myocardial
injury, 74.4% of patients experienced CO-induced cardiomyopathy. All CO-induced
cardiomyopathy recovered to normal status. In this situation, there is no definite approved
reason why more cardiovascular events are occurred in CO poisoned patients with myocardial
injury during long term follow-up period despite normalization of CO-induced elevated TnI and
cardiac dysfunction.
Two image cases related to cardiac magnetic resonance imaging (CMR) in acute CO poisoning
previously reported. One image case reported that patient had mildly depressed left
ventricular (LV) systolic function with hypokinesis of the anterior wall and regional
akinesis of the inferior wall on the transthoracic echocardiography performed during
hospitalization and late gadolinium-enhancement (LGE) images of CMR demonstrated multiple
focal areas of high signal consistent with myocardial necrosis or fibrosis. Another image
case reported an image case that in CMR, inferolateral mid-wall myocardial fibrosis, which
was defined as LGE, was present despite the setting of a completely normal echocardiogram at
4-month follow-up in CO poisoned patients.
Therefore, the investigators evaluate prevalence (frequency of LGE positive) and patterns
(involved LV wall and range of LGE positive) of myocardial fibrosis (LGE positive) in acute
CO-poisoned patients during acute (within seven days after CO exposure) and chronic phase (at
4-5 months after CO exposure) and whether LGE positive developed in acute phase have been
changed through cardiac MRI performed at chronic phase. The investigators also evaluate LV
ejection fraction and global longitudinal strain in transthoracic echocardiography performed
at the ED (baseline) and within seven days (follow-up). The investigators also assessed the
association between neurocognitive outcomes using the global deterioration scale (at 1, 6,
and 12 months after CO exposure) and the presence of LGE positive.
In the US, carbon monoxide (CO) poisoning accounts for 1,300 deaths and 50,000 emergency
department visits annually. Previous report showed that 37% of patients with moderate to
severe CO poisoning experience a myocardial injury defined as elevated cardiac enzyme
[creatine kinase, CK-MB, and cardiac troponin I (TnI)] or ischemic electrocardiogram (ECG)
change. In other study, there was a mortality of 24% of patients during a median follow-up of
7.6 years. A mortality among the patients who experienced the myocardial injury was higher
than patients without the myocardial injury. The death caused by cardiovascular problems
occurred more among patients with a history of the myocardial injury (44% vs. 18%). The
myocardial injury was the major predictor of mortality. In addition, in the Taiwanese
nationwide population-based cohort study, a history of CO poisoning showed a higher risk of a
major adverse cardiovascular event.
The investigators reported that myocardial injury (defined as elevated TnI or change of
ischemic ECG) developed in 20% of CO poisoned patients and elevated TnI was normalized within
65.0 hours. According to previous study of the investigators, among CO poisoned patients with
myocardial injury, 74.4% of patients experienced CO-induced cardiomyopathy. All CO-induced
cardiomyopathy recovered to normal status. In this situation, there is no definite approved
reason why more cardiovascular events are occurred in CO poisoned patients with myocardial
injury during long term follow-up period despite normalization of CO-induced elevated TnI and
cardiac dysfunction.
One case reported an image related to a CO poisoned patient with acute myocardial injury
found by cardiac magnetic resonance imaging (CMR) with a normal coronary artery confirmed by
coronary angiography. In that case, a patient showed that patient had mildly depressed left
ventricular (LV) systolic function with hypokinesis of the anterior wall and regional
akinesis of the inferior wall on the transthoracic echocardiography performed during
hospitalization and late gadolinium-enhancement (LGE) images of CMR demonstrated multiple
focal areas of high signal consistent with myocardial necrosis or fibrosis. Through this
case, the investigators thought that CO poisoning might result in acute myocardial necrosis,
demonstrating another type of myocardial injury that can be detected by CMR. In addition,
Other case reported an image case that in cardiac MRI, inferolateral mid-wall myocardial
fibrosis, which was defined as LGE, was present despite the setting of a completely normal
echocardiogram at 4-month follow-up in a patient who experienced severe CO poisoning.
Mid-wall myocardial fibrosis has been reported in dilated cardiomyopathy (DCMP) of unclear
origin. In a follow-up study of 101 consecutive patients with DCMP, mid-wall fibrosis
(presented in 35% of patients) predicted a combined endpoint of all-cause mortality,
cardiovascular hospitalization, and sudden cardiac death. Myocardial fibrosis has also been
demonstrated in hypertrophic cardiomyopathy. The myocardial fibrosis has been linked to known
markers for sudden cardiac death, although the independent prognostic value of CMR has yet to
be determined.
Through above results, the investigators thought that the normal LV cardiac function may not
reflect that there is no problem with the heart, and it could lead to myocardial fibrosis in
the chronic phase. Myocardial damage seen through CMR may be related to the patient's
prognosis. Therefore, the investigators evaluate prevalence (frequency of LGE positive) and
patterns (involved LV wall and range of LGE positive) of myocardial fibrosis (LGE positive)
in acute CO-poisoned patients during acute (within 7 days after CO exposure) and chronic
phase (at 4-5 months after CO exposure) and whether LGE positive developed in the acute phase
has been changed in cardiac MRI performed at chronic phase. The investigators also evaluate
LV ejection fraction and global longitudinal strain in transthoracic echocardiography
performed at the ED (baseline) and within seven days (follow-up). The investigators also
assessed the association between neurocognitive outcomes using the global deterioration scale
(at 1, 6, and 12 months after CO exposure) and the presence of LGE positive.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03940651 -
Cardiac and Renal Biomarkers in Arthroplasty Surgery
|
Phase 4 | |
Completed |
NCT01688648 -
Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft
|
N/A | |
Completed |
NCT04794062 -
Myocardial Injury and Quality of Life After COVID-19
|
||
Recruiting |
NCT04750616 -
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
|
Phase 2 | |
Recruiting |
NCT04615871 -
Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19
|
Phase 2 | |
Completed |
NCT05691764 -
Effect of Cyclosporine and Remote Ischemic Preconditioning in Reperfusion Ischemia Injury on Tetralogy Fallot Patients With Correction Surgery
|
N/A | |
Withdrawn |
NCT04139655 -
Colchicine Prevents Myocardial Injury After Non-Cardiac Surgery Pilot Study
|
N/A | |
Completed |
NCT04436016 -
PeRiOperaTivE CardioproTection With Ivabradine in Non-cardiac Surgery
|
Phase 4 | |
Completed |
NCT05748691 -
Switching From Cardiac Troponin I to T
|
||
Completed |
NCT03338504 -
Determining the Mechanism of Myocardial Injury and Role of Coronary Disease in Type 2 Myocardial Infarction
|
||
Recruiting |
NCT03013634 -
Protective Effects of Dexmedetomidine on Myocardial Injury During Liver Transplantation
|
N/A | |
Completed |
NCT00007358 -
Dexamethasone Treatment for Congenital Heart Block (CHB) in Newborns With Lupus
|
N/A | |
Recruiting |
NCT05714618 -
MR Evidence of Cardiac Inflammation Post-Stroke
|
||
Recruiting |
NCT04624503 -
Prognostic and Clinical Impact of Cardiovascular Involvement in Patients With COVID-19
|
||
Active, not recruiting |
NCT03339180 -
Cardiac Injury in Patients With Influenza
|
||
Completed |
NCT03010839 -
Cardiopulmonary Protective Effects of Modified Remote Ischaemic Preconditioning in Mitral Valve Replacement Surgery
|
N/A | |
Recruiting |
NCT04743765 -
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
|
N/A | |
Enrolling by invitation |
NCT03253835 -
Cardiac Blood Flow Patterns Associated With Left Ventricular Myocardial Damage
|
||
Completed |
NCT00817791 -
Preconditioning With Hyperbaric Oxygen in Cardiovascular Surgery
|
N/A | |
Completed |
NCT04149314 -
The "Hypotension Prediction Index" in Patients Undergoing Lung Surgery
|
N/A |